Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | WDR5 | P61964 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | RBBP5 | Q15291 | 5/20 | 0.69 |
| ▸ | DPY30 | Q9C005 | 5/20 | 0.69 |
| ▸ | ASH2L | Q9UBL3 | 5/20 | 0.69 |
| ▸ | GRB2 | P62993 | 10/20 | 0.32 |
| ▸ | SIRT2 | Q8IXJ6 | 3/20 | 0.32 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16572495 | 0.94 | WDR5 (0.78) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL15005651 | 0.93 | WDR5 (0.69) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL16572502 | 0.90 | WDR5 (0.65) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL16572500 | 0.90 | WDR5 (0.65) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL16572501 | 0.90 | WDR5 (0.65) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL16572498 | 0.90 | WDR5 (0.65) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL16572497 | 0.90 | WDR5 (0.65) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL16572494 | 0.90 | WDR5 (0.65) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL16572496 | 0.90 | WDR5 (0.65) | WDR5KMT2ARBBP5DPY30ASH2L | |
| SCHEMBL20565510 | 0.88 | WDR5 (0.63) | WDR5KMT2ARBBP5DPY30ASH2L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980838-B2 | Cyclized peptidomimetic small molecule inhibitors of the WDR5 and MLL1 interaction | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2015-03-17 | — | — | US | disclosed |
| US-20130150309-A1 | CYCLIZED PEPTIDOMIMETIC SMALL MOLECULE INHIBITORS OF THE WDR5 AND MLL1 INTERACTION | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130150309-A1 | CYCLIZED PEPTIDOMIMETIC SMALL MOLECULE INHIBITORS OF THE WDR5 AND MLL1 INTERACTION | WDR5, WDR1, WDR77 | WDR5 1/4885KMT2A 37/4885RBBP5 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.